Search

Your search keyword '"Brodowicz, T."' showing total 137 results
Start Over Author "Brodowicz, T." Publication Year Range Last 10 years
137 results on '"Brodowicz, T."'

2. Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

Casali, P.G., Blay, J.Y., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J.V.M.G., Boye, K., Brodowicz, T., Buonadonna, A., De Álava, E., Dei Tos, A.P., Del Muro, X.G., Dufresne, A., Eriksson, M., Fedenko, A., Ferraresi, V., Ferrari, A., Frezza, A.M., Gasperoni, S., Gelderblom, H., Gouin, F., Grignani, G., Haas, R., Hassan, A.B., Hindi, N., Hohenberger, P., Joensuu, H., Jones, R.L., Jungels, C., Jutte, P., Kasper, B., Kawai, A., Kopeckova, K., Krákorová, D.A., Le Cesne, A., Le Grange, F., Legius, E., Leithner, A., Lopez-Pousa, A., Martin-Broto, J., Merimsky, O., Messiou, C., Miah, A.B., Mir, O., Montemurro, M., Morosi, C., Palmerini, E., Pantaleo, M.A., Piana, R., Piperno-Neumann, S., Reichardt, P., Rutkowski, P., Safwat, A.A., Sangalli, C., Sbaraglia, M., Scheipl, S., Schöffski, P., Sleijfer, S., Strauss, D., Strauss, S.J., Hall, K Sundby, Trama, A., Unk, M., van de Sande, M.A.J., van der Graaf, W.T.A., van Houdt, W.J., Frebourg, T., Gronchi, A., and Stacchiotti, S.

Published
2022
Full Text
View/download PDF

3. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

Author

Strauss, S.J., Frezza, A.M., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J.Y., Bolle, S., Bonvalot, S., Boukovinas, I., Bovee, J.V.M.G., Boye, K., Brennan, B., Brodowicz, T., Buonadonna, A., de Álava, E., Dei Tos, A.P., Garcia del Muro, X., Dufresne, A., Eriksson, M., Fagioli, F., Fedenko, A., Ferraresi, V., Ferrari, A., Gaspar, N., Gasperoni, S., Gelderblom, H., Gouin, F., Grignani, G., Gronchi, A., Haas, R., Hassan, A.B., Hecker-Nolting, S., Hindi, N., Hohenberger, P., Joensuu, H., Jones, R.L., Jungels, C., Jutte, P., Kager, L., Kasper, B., Kawai, A., Kopeckova, K., Krákorová, D.A., Le Cesne, A., Le Grange, F., Legius, E., Leithner, A., López Pousa, A., Martin-Broto, J., Merimsky, O., Messiou, C., Miah, A.B., Mir, O., Montemurro, M., Morland, B., Morosi, C., Palmerini, E., Pantaleo, M.A., Piana, R., Piperno-Neumann, S., Reichardt, P., Rutkowski, P., Safwat, A.A., Sangalli, C., Sbaraglia, M., Scheipl, S., Schöffski, P., Sleijfer, S., Strauss, D., Sundby Hall, K., Trama, A., Unk, M., van de Sande, M.A.J., van der Graaf, W.T.A., van Houdt, W.J., Frebourg, T., Ladenstein, R., Casali, P.G., and Stacchiotti, S.

Published
2021
Full Text
View/download PDF

4. Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

Author

Gronchi, A., Miah, A.B., Dei Tos, A.P., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J.Y., Bolle, S., Bonvalot, S., Boukovinas, I., Bovee, J.V.M.G., Boye, K., Brennan, B., Brodowicz, T., Buonadonna, A., De Álava, E., Del Muro, X.G., Dufresne, A., Eriksson, M., Fagioli, F., Fedenko, A., Ferraresi, V., Ferrari, A., Frezza, A.M., Gasperoni, S., Gelderblom, H., Gouin, F., Grignani, G., Haas, R., Hassan, A.B., Hecker-Nolting, S., Hindi, N., Hohenberger, P., Joensuu, H., Jones, R.L., Jungels, C., Jutte, P., Kager, L., Kasper, B., Kawai, A., Kopeckova, K., Krákorová, D.A., Le Cesne, A., Le Grange, F., Legius, E., Leithner, A., Lopez-Pousa, A., Martin-Broto, J., Merimsky, O., Messiou, C., Mir, O., Montemurro, M., Morland, B., Morosi, C., Palmerini, E., Pantaleo, M.A., Piana, R., Piperno-Neumann, S., Reichardt, P., Rutkowski, P., Safwat, A.A., Sangalli, C., Sbaraglia, M., Scheipl, S., Schöffski, P., Sleijfer, S., Strauss, D., Strauss, S., Sundby Hall, K., Trama, A., Unk, M., van de Sande, M.A.J., van der Graaf, W.T.A., van Houdt, W.J., Frebourg, T., Casali, P.G., and Stacchiotti, S.

Published
2021
Full Text
View/download PDF

5. Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts

Author

Stacchiotti, S., Miah, A.B., Frezza, A.M., Messiou, C., Morosi, C., Caraceni, A., Antonescu, C.R., Bajpai, J., Baldini, E., Bauer, S., Biagini, R., Bielack, S., Blay, J.Y., Bonvalot, S., Boukovinas, I., Bovee, J.V.M.G., Boye, K., Brodowicz, T., Callegaro, D., De Alava, E., Deoras-Sutliff, M., Dufresne, A., Eriksson, M., Errani, C., Fedenko, A., Ferraresi, V., Ferrari, A., Fletcher, C.D.M., Garcia del Muro, X., Gelderblom, H., Gladdy, R.A., Gouin, F., Grignani, G., Gutkovich, J., Haas, R., Hindi, N., Hohenberger, P., Huang, P., Joensuu, H., Jones, R.L., Jungels, C., Kasper, B., Kawai, A., Le Cesne, A., Le Grange, F., Leithner, A., Leonard, H., Lopez Pousa, A., Martin Broto, J., Merimsky, O., Merriam, P., Miceli, R., Mir, O., Molinari, M., Montemurro, M., Oldani, G., Palmerini, E., Pantaleo, M.A., Patel, S., Piperno-Neumann, S., Raut, C.P., Ravi, V., Razak, A.R.A., Reichardt, P., Rubin, B.P., Rutkowski, P., Safwat, A.A., Sangalli, C., Sapisochin, G., Sbaraglia, M., Scheipl, S., Schöffski, P., Strauss, D., Strauss, S.J., Sundby Hall, K., Tap, W.D., Trama, A., Tweddle, A., van der Graaf, W.T.A., Van De Sande, M.A.J., Van Houdt, W., van Oortmerssen, G., Wagner, A.J., Wartenberg, M., Wood, J., Zaffaroni, N., Zimmermann, C., Casali, P.G., Dei Tos, A.P., and Gronchi, A.

Published
2021
Full Text
View/download PDF

6. Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

Casali, P.G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J V M G, Brodowicz, T., Broto, J.M., Buonadonna, A., De Álava, E., Dei Tos, A.P., Del Muro, X.G., Dileo, P., Eriksson, M., Fedenko, A., Ferraresi, V., Ferrari, A., Ferrari, S., Frezza, A.M., Gasperoni, S., Gelderblom, H., Gil, T., Grignani, G., Gronchi, A., Haas, R.L., Hannu, A., Hassan, B., Hohenberger, P., Issels, R., Joensuu, H., Jones, R.L., Judson, I., Jutte, P., Kaal, S., Kasper, B., Kopeckova, K., Krákorová, D.A., Le Cesne, A., Lugowska, I., Merimsky, O., Montemurro, M., Pantaleo, M.A., Piana, R., Picci, P., Piperno-Neumann, S., Pousa, A.L., Reichardt, P., Robinson, M.H., Rutkowski, P., Safwat, A.A., Schöffski, P., Sleijfer, S., Stacchiotti, S., Sundby Hall, K., Unk, M., Van Coevorden, F., Van der Graaf, W., Whelan, J., Wardelmann, E., Zaikova, O., and Blay, J.Y.

Published
2018
Full Text
View/download PDF

7. Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

Casali, P.G., Bielack, S., Abecassis, N., Aro, H.T., Bauer, S., Biagini, R., Bonvalot, S., Boukovinas, I., Bovee, J V M G, Brennan, B., Brodowicz, T., Broto, J.M., Brugières, L., Buonadonna, A., De Álava, E., Dei Tos, A.P., Del Muro, X.G., Dileo, P., Dhooge, C., Eriksson, M., Fagioli, F., Fedenko, A., Ferraresi, V., Ferrari, A., Ferrari, S., Frezza, A.M., Gaspar, N., Gasperoni, S., Gelderblom, H., Gil, T., Grignani, G., Gronchi, A., Haas, R.L., Hassan, B., Hecker-Nolting, S., Hohenberger, P., Issels, R., Joensuu, H., Jones, R.L., Judson, I., Jutte, P., Kaal, S., Kager, L., Kasper, B., Kopeckova, K., Krákorová, D.A., Ladenstein, R., Le Cesne, A., Lugowska, I., Merimsky, O., Montemurro, M., Morland, B., Pantaleo, M.A., Piana, R., Picci, P., Piperno-Neumann, S., Pousa, A.L., Reichardt, P., Robinson, M.H., Rutkowski, P., Safwat, A.A., Schöffski, P., Sleijfer, S., Stacchiotti, S., Strauss, S.J., Sundby Hall, K., Unk, M., Van Coevorden, F., van der Graaf, W.T.A., Whelan, J., Wardelmann, E., Zaikova, O., and Blay, J.Y.

Published
2018
Full Text
View/download PDF

8. Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

Casali, P.G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J.V.M.G., Brodowicz, T., Broto, J.M., Buonadonna, A., De Álava, E., Dei Tos, A.P., Del Muro, X.G., Dileo, P., Eriksson, M., Fedenko, A., Ferraresi, V., Ferrari, A., Ferrari, S., Frezza, A.M., Gasperoni, S., Gelderblom, H., Gil, T., Grignani, G., Gronchi, A., Haas, R.L., Hannu, A., Hassan, B., Hohenberger, P., Issels, R., Joensuu, H., Jones, R.L., Judson, I., Jutte, P., Kaal, S., Kasper, B., Kopeckova, K., Krákorová, D.A., Le Cesne, A., Lugowska, I., Merimsky, O., Montemurro, M., Pantaleo, M.A., Piana, R., Picci, P., Piperno-Neumann, S., Pousa, A.L., Reichardt, P., Robinson, M.H., Rutkowski, P., Safwat, A.A., Schöffski, P., Sleijfer, S., Stacchiotti, S., Sundby Hall, K., Unk, M., Van Coevorden, F., Van der Graaf, W., Whelan, J., Wardelmann, E., Zaikova, O., and Blay, J.Y.

Published
2018
Full Text
View/download PDF

13. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

Casali, Paolo G., Blay, Jean-Yves, Abecassis, N., Bajpai, J., Bauer, Sebastian, Biagini, R., Bielack, S., Bonvalot, Sylvie, Boukovinas, I., Bovee, J. V. M. G., Boye, K., Brodowicz, T., Buonadonna, A., Álava, Enrique de, Tos, A. P. dei, García del Muro, Xavier, Dufresne, Armelle, Eriksson, Mikael, Fedenko, Alexander, Ferraresi, Virginia, Ferrari, A., Frezza, Anna M., Gasperoni, Silvia, Gelderblom, Hans, Gouin, Francois, Grignani, Giovanni, Haas, R. L., Hassan, A. B., Hindi, Nadia, Hohenberger, Peter, Joensuu, Heikki, Jones, Robin L., Jungels, C., Jutte, P., Kasper, Bernd, Kawai, Akira, Kopeckova, K., Krákorová, D. A., Le Cesne, A, Le Grange, F, Legius, E., Leithner, Andreas, López-Pousa, Antonio, Martín-Broto, Javier, Merimsky, O., Messiou, C., Miah, A. B., Mir, Olivier, Montemurro, M., Morosi, Carlo, Palmerini, Emanuela, Pantaleo, M. A., Piana, R., Piperno-Neumann, S., Reichardt, Peter, Rutkowski, Piotr, Safwat, A. A., Sangalli, C., Sbaraglia, Marta, Scheipl, S., Schöffski, P., Sleijfer, S., Strauss, D., Strauss, S. J., Sundby-Hall, Kirsten, Trama, A., Unk, M., Sande, M. A. J. van de, Graaf, W.T.A. van der, Houdt, W. J. van, Frebourg, T., Gronchi, Alesandro, Stacchiotti, Silvia, ESMO Guidelines Committee, EURACAN, GENTURIS, Casali, Paolo G., Blay, Jean-Yves, Abecassis, N., Bajpai, J., Bauer, Sebastian, Biagini, R., Bielack, S., Bonvalot, Sylvie, Boukovinas, I., Bovee, J. V. M. G., Boye, K., Brodowicz, T., Buonadonna, A., Álava, Enrique de, Tos, A. P. dei, García del Muro, Xavier, Dufresne, Armelle, Eriksson, Mikael, Fedenko, Alexander, Ferraresi, Virginia, Ferrari, A., Frezza, Anna M., Gasperoni, Silvia, Gelderblom, Hans, Gouin, Francois, Grignani, Giovanni, Haas, R. L., Hassan, A. B., Hindi, Nadia, Hohenberger, Peter, Joensuu, Heikki, Jones, Robin L., Jungels, C., Jutte, P., Kasper, Bernd, Kawai, Akira, Kopeckova, K., Krákorová, D. A., Le Cesne, A, Le Grange, F, Legius, E., Leithner, Andreas, López-Pousa, Antonio, Martín-Broto, Javier, Merimsky, O., Messiou, C., Miah, A. B., Mir, Olivier, Montemurro, M., Morosi, Carlo, Palmerini, Emanuela, Pantaleo, M. A., Piana, R., Piperno-Neumann, S., Reichardt, Peter, Rutkowski, Piotr, Safwat, A. A., Sangalli, C., Sbaraglia, Marta, Scheipl, S., Schöffski, P., Sleijfer, S., Strauss, D., Strauss, S. J., Sundby-Hall, Kirsten, Trama, A., Unk, M., Sande, M. A. J. van de, Graaf, W.T.A. van der, Houdt, W. J. van, Frebourg, T., Gronchi, Alesandro, Stacchiotti, Silvia, ESMO Guidelines Committee, EURACAN, and GENTURIS

Abstract

Gastrointestinal stromal tumours (GISTs) are malignant mesenchymal tumours with a variable clinical behaviour, marked by differentiation towards the interstitial cells of Cajal.1 GISTs belong to the family of soft tissue sarcomas (STSs) but are treated separately due to their peculiar histogenesis, clinical behaviour and specific therapy. This European Society for Medical Oncology (ESMO)–European Reference Network for Rare Adult Solid Cancers (EURACAN)–European Reference Network for Genetic Tumour Risk Syndromes (GENTURIS) Clinical Practice Guideline (CPG) will cover GISTs while other STSs are covered in the ESMO–EURACAN–European Reference Network for Paediatric Oncology (ERN PaedCan)–GENTURIS STS CPG.

Published
2022

14. 415P Comparison of cetuximab every 2 weeks versus standard once-weekly administration for the first-line treatment of RAS wild-type metastatic colorectal cancer among patients with left- and right-sided primary tumor location

Author

Kasper, S., primary, Cheng, A-L., additional, Rouyer, M., additional, Foch, C., additional, Lamy, F-X., additional, Esser, R., additional, Batech, M., additional, Wong, C.M.J., additional, Zhang, A., additional, Brodowicz, T., additional, and Zielinski, C., additional

Published
2021
Full Text
View/download PDF

15. P-52 Overall survival with cetuximab every 2 weeks vs standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumor location

Author

Kasper, S., primary, Cheng, A., additional, Rouyer, M., additional, Foch, C., additional, Lamy, F., additional, Esser, R., additional, Batech, M., additional, Wong, C., additional, Zhang, A., additional, Brodowicz, T., additional, and Zielinski, C., additional

Published
2021
Full Text
View/download PDF

16. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

Author

European Society for Medical Oncology, Strauss, S. J., Frezza, Anna M., Abecassis, N., Bajpai, J., Bauer, Sebastian, Biagini, R., Bielack, S., Blay, Jean-Yves, Bolle, S., Bonvalot, Sylvie, Boukovinas, I., Bovee, J. V. M. G., Boye, K., Brennan, Bernadette, Brodowicz, T., Buonadonna, A., Álava, Enrique de, Dei Tos, Angelo Paolo, García del Muro, Xavier, Dufresne, Armelle, Eriksson, Mikael, Fagioli, F., Fedenko, Alexander, Ferraresi, Virginia, Ferrari, A., Gaspar, Nathalie, Gasperoni, Silvia, Gelderblom, Hans, Gouin, Francois, Grignani, Giovanni, Gronchi, Alesandro, Haas, R. L., Hassan, A. B., Hecker-Nolting, S., Hindi, Nadia, Hohenberger, Peter, Joensuu, Heikki, Jones, Robin L., Jungels, C., Jutte, P., Kager, L., Kasper, Bernd, Kawai, Akira, Kopeckova, K., Krákorová, D. A., Le Cesne, Axel, Le Grange, F., Legius, E., Leithner, Andreas, López-Pousa, Antonio, Martín-Broto, Javier, Merimsky, O., Messiou, C., Miah, A. B., Mir, Olivier, Montemurro, M., Morland, B., Morosi, Carlo, Palmerini, Emanuela, Pantaleo, M. A., Piana, R., Piperno-Neumann, S., Reichardt, Peter, Rutkowski, Piotr, Safwat, A. A., Sangalli, C., Sbaraglia, Marta, Scheipl, S., Schöffski, P., Sleijfer, S., Strauss, D., Sundby Hall, K., Trama, A., Unk, M., van de Sande, Michiel, van der Graaf, W. T., van Houdt, W. J., Frebourg, T., Ladenstein, Rudolf, Casali, Paolo G., Stacchiotti, Silvia, European Society for Medical Oncology, Strauss, S. J., Frezza, Anna M., Abecassis, N., Bajpai, J., Bauer, Sebastian, Biagini, R., Bielack, S., Blay, Jean-Yves, Bolle, S., Bonvalot, Sylvie, Boukovinas, I., Bovee, J. V. M. G., Boye, K., Brennan, Bernadette, Brodowicz, T., Buonadonna, A., Álava, Enrique de, Dei Tos, Angelo Paolo, García del Muro, Xavier, Dufresne, Armelle, Eriksson, Mikael, Fagioli, F., Fedenko, Alexander, Ferraresi, Virginia, Ferrari, A., Gaspar, Nathalie, Gasperoni, Silvia, Gelderblom, Hans, Gouin, Francois, Grignani, Giovanni, Gronchi, Alesandro, Haas, R. L., Hassan, A. B., Hecker-Nolting, S., Hindi, Nadia, Hohenberger, Peter, Joensuu, Heikki, Jones, Robin L., Jungels, C., Jutte, P., Kager, L., Kasper, Bernd, Kawai, Akira, Kopeckova, K., Krákorová, D. A., Le Cesne, Axel, Le Grange, F., Legius, E., Leithner, Andreas, López-Pousa, Antonio, Martín-Broto, Javier, Merimsky, O., Messiou, C., Miah, A. B., Mir, Olivier, Montemurro, M., Morland, B., Morosi, Carlo, Palmerini, Emanuela, Pantaleo, M. A., Piana, R., Piperno-Neumann, S., Reichardt, Peter, Rutkowski, Piotr, Safwat, A. A., Sangalli, C., Sbaraglia, Marta, Scheipl, S., Schöffski, P., Sleijfer, S., Strauss, D., Sundby Hall, K., Trama, A., Unk, M., van de Sande, Michiel, van der Graaf, W. T., van Houdt, W. J., Frebourg, T., Ladenstein, Rudolf, Casali, Paolo G., and Stacchiotti, Silvia

Published
2021

17. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

Casali, P G, Abecassis, N, Aro, H T, Bauer, S, Biagini, R, Bielack, S, Bonvalot, S, Boukovinas, I, Bovee, J V M G, Brodowicz, T, Broto, J M, Buonadonna, A, De Álava, E, Dei Tos, A P, Del Muro, X G, Dileo, P, Eriksson, M, Fedenko, A, Ferraresi, V, Ferrari, A, Ferrari, S, Frezza, A M, Gasperoni, S, Gelderblom, H, Gil, T, Grignani, G, Gronchi, A, Haas, R L, Hassan, B, Hohenberger, P, Issels, R, Joensuu, H, Jones, R L, Judson, I, Jutte, P, Kaal, S, Kasper, B, Kopeckova, K, Krákorová, D A, Le Cesne, A, Lugowska, I, Merimsky, O, Montemurro, M, Pantaleo, M A, Piana, R, Picci, P, Piperno-Neumann, S, Pousa, A L, Reichardt, P, and Safwat, A A

Published
2018
Full Text
View/download PDF

18. Prior exposure to pazopanib (PAZ) did not minor efficacy of regorafenib (REG) in non-adipocytic soft tissue sarcoma patients (pts)

Author

Penel, N., primary, Blay, J.-Y., additional, Wallet, J., additional, Mir, O., additional, Italiano, A., additional, Bertucci, F., additional, Piperno-Neumann, S., additional, Brodowicz, T., additional, Bompas, E., additional, Liegl-Atzwanger, B., additional, Chevreau, C.M., additional, Ray-Coquard, I.L., additional, Taieb, S., additional, Decoupigny, E., additional, Deley, M C Le, additional, and Le Cesne, A., additional

Published
2019
Full Text
View/download PDF

19. Noninferiority on overall survival of every-2-weeks vs weekly schedule of cetuximab for first-line treatment of RAS wild-type metastatic colorectal cancer

Author

Kasper, S., primary, Cheng, A.-L., additional, Overkamp, F., additional, Rouyer, M., additional, Foch, C., additional, Lamy, F.-X., additional, Esser, R., additional, Messinger, D., additional, Rothe, V., additional, Chen, W., additional, Brodowicz, T., additional, and Zielinski, C.C., additional

Published
2019
Full Text
View/download PDF

20. Regosarc: regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-a quality-adjusted time without symptoms of progression or toxicity analysis

Author

Berry, V. (Vincent), Basson, L. (Laurent), Bogart, E. (Emilie), Mir, O. (Olivier), Blay, J-Y. (Jean-Yves), Italiano, A. (Antoine), Bertucci, F. (François), Chevreau, C. (Christine), Clisant-Delaine, S. (Stephanie), Liegl-Atzwanger, B. (Bernadette), Tresch-Bruneel, E. (Emmanuelle), Wallet, J. (Jennifer), Taieb, S. (Sophie), Decoupigny, E. (Emilie), Le Cesne, A. (Axel), Brodowicz, T. (Thomas), Penel, N. (Nicolas), Site de Recherche Intégrée en Cancérologie (SIRIC-ONCOLille), Université de Lille, Sciences et Technologies-Université de Lille, Sciences Humaines et Sociales-Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université de Lille-UNICANCER-Université de Lille-UNICANCER-Cancéropole Nord-Ouest-Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université de Lille-UNICANCER, Institut Gustave Roussy (IGR), Centre Léon Bérard [Lyon], Institut Bergonié [Bordeaux], UNICANCER, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Institut Claudius Regaud, Karl-Franzens-Universität Graz, University of Vienna [Vienna], Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université Lille Nord de France (COMUE)-UNICANCER-Université Lille Nord de France (COMUE)-UNICANCER-Cancéropole Nord-Ouest-Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université Lille Nord de France (COMUE)-UNICANCER, Karl-Franzens-Universität [Graz, Autriche], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille, CHU Lille, Université de Lille, Site de Recherche Intégrée en Cancérologie [SIRIC-ONCOLille], METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694, Institut Gustave Roussy [IGR], and Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]

Subjects
[SDV]Life Sciences [q-bio], Mesh:Diarrhea/chemically induced, Mesh:Alopecia/chemically induced, Mesh:Phenylurea Compounds/therapeutic use, Mesh:Aged, Mesh:Synovial/drug therapy, Mesh:Treatment Outcome, Mesh:Anorexia/chemically induced, Mesh:Quality of Life, Mesh:Proportional Hazards Models, Mesh:Severity of Illness Index, Mesh:Female, quality-adjusted survival, Mesh:Fecal Incontinence/chemically induced, Mesh:Male, Mesh:Sarcoma, Mesh:Middle Aged, quality-adjusted time without symptoms of progression or toxicity (Q-TWiST), Mesh:Asthenia/chemically induced, Mesh:Liposarcoma/drug therapy, metastatic soft-tissue sarcoma, placebo, regorafenib, Mesh:Mucositis/chemically induced, Mesh:Hospitalization, Mesh:Sarcoma/drug therapy, Mesh:Hand-Foot Syndrome/etiology, Mesh:Pyridines/therapeutic use, Mesh:Antineoplastic Agents/therapeutic use, Mesh:Leiomyosarcoma/drug therapy, Mesh:Humans, Mesh:Hypertension/chemically induced, Mesh:Double-Blind Method
Abstract

International audience; BACKGROUND: In a placebo-controlled, randomized phase 2 trial (ClinicalTrials.gov identifier NCT01900743), regorafenib improved progression-free survival (PFS) for patients with doxorubicin-pretreated advanced nonadipocytic sarcoma. A quality-adjusted time without symptoms of progression or toxicity (Q-TWiST) post hoc exploratory analysis was applied to provide an integrated measure of its clinical benefit.METHODS: In the base-case analysis, each patient's overall survival (OS) was partitioned into 3 mutually exclusive health states: the time with a grade 3 or 4 adverse event (TOX), the time without symptoms of disease or grade 3 or 4 toxicity from treatment, and the time after tumor progression or relapse. The time spent in each state was weighted with a health-state utility associated with that state and was summed to calculate the Q-TWiST. The stability of the base-case analysis was explored with several sensitivity analyses.RESULTS: In nonadipocytic sarcoma, the PFS was (4.0 months [2.6-5.5 months] with regorafenib vs 1.0 month [0.9-1.8 months] with a placebo; hazard ratio, 0.36 [0.25-0.53]; P < .0001); the OS was 13.4 months (8.6-17.3 months) with regorafenib and 9.0 months (6.8-12.5 months) with a placebo (hazard ratio, 0.67 [0.44-1.02]). With the classic definition of TOX (including all grade 3 and 4 clinical adverse events), the Q-TWiSTs were 8.0 months (7.0-9.0 months) with regorafenib and 5.7 months (4.9-6.4 months) with a placebo (P

Published
2017
Full Text
View/download PDF

21. Corrections to “Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”

Author

Casali, P.G., primary, Abecassis, N., additional, Aro, H.T., additional, Bauer, S., additional, Biagini, R., additional, Bielack, S., additional, Bonvalot, S., additional, Boukovinas, I., additional, Bovee, J V M G, additional, Brodowicz, T., additional, Broto, J.M., additional, Buonadonna, A., additional, De Álava, E., additional, Dei Tos, A.P., additional, Del Muro, X.G., additional, Dileo, P., additional, Eriksson, M., additional, Fedenko, A., additional, Ferraresi, V., additional, Ferrari, A., additional, Ferrari, S., additional, Frezza, A.M., additional, Gasperoni, S., additional, Gelderblom, H., additional, Gil, T., additional, Grignani, G., additional, Gronchi, A., additional, Haas, R.L., additional, Hassan, B., additional, Hohenberger, P., additional, Issels, R., additional, Joensuu, H., additional, Jones, R.L., additional, Judson, I., additional, Jutte, P., additional, Kaal, S., additional, Kasper, B., additional, Kopeckova, K., additional, Krákorová, D.A., additional, Le Cesne, A., additional, Lugowska, I., additional, Merimsky, O., additional, Montemurro, M., additional, Pantaleo, M.A., additional, Piana, R., additional, Picci, P., additional, Piperno-Neumann, S., additional, Pousa, A.L., additional, Reichardt, P., additional, Robinson, M.H., additional, Rutkowski, P., additional, Safwat, A.A., additional, Schöffski, P., additional, Sleijfer, S., additional, Stacchiotti, S., additional, Sundby Hall, K., additional, Unk, M., additional, Van Coevorden, F., additional, van der Graaf, W.T.A., additional, Whelan, J., additional, Wardelmann, E., additional, Zaikova, O., additional, and Blay, J.Y., additional

Published
2018
Full Text
View/download PDF

22. Corrections to “Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”

Author

Casali, P.G., primary, Abecassis, N., additional, Aro, H.T., additional, Bauer, S., additional, Biagini, R., additional, Bielack, S., additional, Bonvalot, S., additional, Boukovinas, I., additional, Bovee, J V M G, additional, Brodowicz, T., additional, Broto, J.M., additional, Buonadonna, A., additional, De Álava, E., additional, Dei Tos, A.P., additional, Del Muro, X.G., additional, Dileo, P., additional, Eriksson, M., additional, Fedenko, A., additional, Ferraresi, V., additional, Ferrari, A., additional, Ferrari, S., additional, Frezza, A.M., additional, Gasperoni, S., additional, Gelderblom, H., additional, Gil, T., additional, Grignani, G., additional, Gronchi, A., additional, Haas, R.L., additional, Hassan, B., additional, Hohenberger, P., additional, Issels, R., additional, Joensuu, H., additional, Jones, R.L., additional, Judson, I., additional, Jutte, P., additional, Kaal, S., additional, Kasper, B., additional, Kopeckova, K., additional, Krákorová, D.A., additional, Le Cesne, A., additional, Lugowska, I., additional, Merimsky, O., additional, Montemurro, M., additional, Pantaleo, M.A., additional, Piana, R., additional, Picci, P., additional, Piperno-Neumann, S., additional, Pousa, A.L., additional, Reichardt, P., additional, Robinson, M.H., additional, Rutkowski, P., additional, Safwat, A.A., additional, Schöffski, P., additional, Sleijfer, S., additional, Stacchiotti, S., additional, Sundby Hall, K., additional, Unk, M., additional, Van Coevorden, F., additional, van der Graaf, W.T.A., additional, Whelan, J., additional, Wardelmann, E., additional, Zaikova, O., additional, and Blay, J.Y., additional

Published
2018
Full Text
View/download PDF

23. Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

Casali, Paolo G., Bielack, S., Abecassis, N., Aro, H. T., Bauer, Sebastian, Biagini, R., Bonvalot, Sylvie, Boukovinas, I., Bovee, J. V. M. G., Brennan, Bernadette, Brodowicz, T., Martín-Broto, Javier, Brugières, L., Buonadonna, A., Álava, Enrique de, Dei Tos, Angelo Paolo, García del Muro, Xavier, Dileo, P., Dhooge, C., Eriksson, Mikael, Fagioli, F., Fedenko, Alexander, Ferraresi, Virginia, Ferrari, A., Frezza, Anna M., Gaspar, Nathalie, Gasperoni, Silvia, Gelderblom, Hans, Gil, T., Grignani, Giovanni, Gronchi, Alesandro, Haas, R. L., Hassan, B., Hecker-Nolting, S., Hohenberger, Peter, Issels, R., Joensuu, Heikki, Jones, Robin L., Judson, I., Jutte, P., Kaal, S., Kager, L., Kasper, Bernd, Kopeckova, K., Krákorová, D. A., Ladenstein, Rudolf, Le Cesne, Axel, Lugowska, Iwona, Merimsky, O., Montemurro, M., Morland, B., Pantaleo, M. A., Piana, R., Picci, Piero, Piperno-Neumann, S., Pousa, A. L., Reichardt, Peter, Robinson, M. H., Rutkowski, Piotr, Safwat, A. A., Schöffski, P., Sleijfer, S., Stacchiotti, Silvia, Strauss, Sandra, Sundby Hall, K., Unk, M., van Coevorden, F., van der Graaf, W. T., Whelan, Jeremy, Wardelmann, Eva, Zaikova, O., Blay, Jean-Yves, Casali, Paolo G., Bielack, S., Abecassis, N., Aro, H. T., Bauer, Sebastian, Biagini, R., Bonvalot, Sylvie, Boukovinas, I., Bovee, J. V. M. G., Brennan, Bernadette, Brodowicz, T., Martín-Broto, Javier, Brugières, L., Buonadonna, A., Álava, Enrique de, Dei Tos, Angelo Paolo, García del Muro, Xavier, Dileo, P., Dhooge, C., Eriksson, Mikael, Fagioli, F., Fedenko, Alexander, Ferraresi, Virginia, Ferrari, A., Frezza, Anna M., Gaspar, Nathalie, Gasperoni, Silvia, Gelderblom, Hans, Gil, T., Grignani, Giovanni, Gronchi, Alesandro, Haas, R. L., Hassan, B., Hecker-Nolting, S., Hohenberger, Peter, Issels, R., Joensuu, Heikki, Jones, Robin L., Judson, I., Jutte, P., Kaal, S., Kager, L., Kasper, Bernd, Kopeckova, K., Krákorová, D. A., Ladenstein, Rudolf, Le Cesne, Axel, Lugowska, Iwona, Merimsky, O., Montemurro, M., Morland, B., Pantaleo, M. A., Piana, R., Picci, Piero, Piperno-Neumann, S., Pousa, A. L., Reichardt, Peter, Robinson, M. H., Rutkowski, Piotr, Safwat, A. A., Schöffski, P., Sleijfer, S., Stacchiotti, Silvia, Strauss, Sandra, Sundby Hall, K., Unk, M., van Coevorden, F., van der Graaf, W. T., Whelan, Jeremy, Wardelmann, Eva, Zaikova, O., and Blay, Jean-Yves

Published
2018

24. EORTC experience with advanced/metastatic epithelioid sarcoma patients treated in prospective trials: Clinical profile and response to systemic therapy

Author

Touati, N., primary, Schoffski, P., additional, Litière, S., additional, Judson, I., additional, Sleijfer, S., additional, van der Graaf, W.T.A., additional, Italiano, A., additional, Isambert, N., additional, Gil, T., additional, Blay, J.-Y., additional, Stark, D., additional, Brodowicz, T., additional, Marreaud, S., additional, and Gronchi, A., additional

Published
2017
Full Text
View/download PDF

27. Third CECOG consensus on the systemic treatment of non-small-cell lung cancer

Author

Brodowicz, T., Ciuleanu, T., Crawford, J., Filipits, M., Fischer, J. R., Georgoulias, V., Gridelli, C., Hirsch, F. R., Jassem, J., Kosmidis, P., Krzakowski, M., Manegold, Ch, Pujol, J. L., Stahel, R., Thatcher, N., Vansteenkiste, J., Minichsdorfer, C., Zöchbauer-Müller, S., Pirker, R., Zielinski, C. C., Brodowicz, T., Ciuleanu, T., Crawford, J., Filipits, M., Fischer, J. R., Georgoulias, V., Gridelli, C., Hirsch, F. R., Jassem, J., Kosmidis, P., Krzakowski, M., Manegold, Ch, Pujol, J. L., Stahel, R., Thatcher, N., Vansteenkiste, J., Minichsdorfer, C., Zöchbauer-Müller, S., Pirker, R., and Zielinski, C. C.

Abstract

The current third consensus on the systemic treatment of non-small-cell lung cancer (NSCLC) builds upon and updates similar publications on the subject by the Central European Cooperative Oncology Group (CECOG), which has published such consensus statements in the years 2002 and 2005 (Zielinski CC, Beinert T, Crawford J et al. Consensus on medical treatment of non-small-cell lung cancer—update 2004. Lung Cancer 2005; 50: 129-137). The principle of all CECOG consensus is such that evidence-based recommendations for state-of-the-art treatment are given upon which all participants and authors of the manuscript have to agree (Beslija S, Bonneterre J, Burstein HJ et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20 (11): 1771-1785). This is of particular importance in diseases in which treatment options depend on very particular clinical and biologic variables (Zielinski CC, Beinert T, Crawford J et al. Consensus on medical treatment of non-small-cell lung cancer—update 2004. Lung Cancer 2005; 50: 129-137; Beslija S, Bonneterre J, Burstein HJ et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20 (11): 1771-1785). Since the publication of the last CECOG consensus on the medical treatment of NSCLC, a series of diagnostic tools for the characterization of biomarkers for personalized therapy for NSCLC as well as therapeutic options including adjuvant treatment, targeted therapy, and maintenance treatment have emerged and strongly influenced the field. Thus, the present third consensus was generated that not only readdresses previous disease-related issues but also expands toward recent developments in the management of NSCLC. It is the aim of the present consensus to summarize minimal quality-oriented requirements for individual patients with NSCLC in its various stages based upon levels of evidence in the light of a rapidly expanding array of individual therapeutic options

Published
2017

33. A gastrointestinal stromal tumourmimicking solid pseudopapillary neoplasia of the pancreas--a case report.

Author

Müller, C., Beer, A., Wrba, F., Brodowicz, T., Bastati, N., Ba-Ssalamah, A., and Schindl, M.

Abstract

Background Diagnosis of large, heterogenous lesions of the pancreas with solid and cystic components is often challenging. The spectrum of differential diagnoses is broad, and clinical as well as radiological findings may be similar. Methods Detailed analysis of a clinical case and review of literature. Results We present the case of a 28-year-old woman with a large, heterogenous tumour of the pancreatic head that was incidentally found in routine ultrasound during pregnancy. The presence of a solid pseudopapillary neoplasm (SPN) was suspected because of typical clinical and radiological characteristics. The patient underwent partial pancreatoduodenectomy and surprisingly, histological work-up confirmed a pancreatic extra-gastrointestinal stromal tumour (EGIST). Conclusion As clinical and radiological findings may be misleading in a large, heterogenous tumour of the pancreas, a biopsy with histological proof of diagnosis is recommended, especially in situations where a neoadjuvant treatment may be considered. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

34. 1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

Author

Zielinski, C.C., primary, Lang, I., additional, Inbar, M., additional, Kahan, Z., additional, Greil, R., additional, Beslija, S., additional, Stemmer, S.M., additional, Zvirbule, Z., additional, Steger, G.G., additional, Melichar, B., additional, Pienkowski, T., additional, Sirbu, D., additional, Petruzelka, L., additional, Eniu, A., additional, Nisenbaum, B., additional, Dank, M., additional, Anghel, R., additional, Messinger, D., additional, and Brodowicz, T., additional

Published
2015
Full Text
View/download PDF

41. Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts

Author

Peter Reichardt, C. Zimmermann, Emanuela Palmerini, Paul H. Huang, G. Oldani, R. Biagini, Silvia Stacchiotti, Akira Kawai, H. Leonard, A. P. Dei Tos, Andrew J. Wagner, Mikael Eriksson, Alessandro Gronchi, Kjetil Boye, Peter Hohenberger, X. Garcia del Muro, C. Errani, Annalisa Trama, Andreas Leithner, Maria Abbondanza Pantaleo, Dirk C. Strauss, Christopher D.M. Fletcher, F. le Grange, W.J. van Houdt, Judith V.M.G. Bovée, Rick L. Haas, J. Gutkovich, Heikki Joensuu, J. Martin Broto, François Gouin, A.M. Frezza, Elizabeth H. Baldini, A. Le Cesne, Akmal Safwat, Armelle Dufresne, Susanne Scheipl, W.T.A. van der Graaf, Shreyaskumar Patel, J. Wood, Robin L. Jones, M. Molinari, Stefan S. Bielack, K. Sundby Hall, Jean-Yves Blay, Nadia Hindi, Sandra J. Strauss, Sylvie Bonvalot, Christina Messiou, Virginia Ferraresi, V. Ravi, E. de Álava, Aisha Miah, Piotr Rutkowski, A. Lopez Pousa, William D. Tap, Sophie Piperno-Neumann, Rosalba Miceli, Augusto Caraceni, G. van Oortmerssen, Rebecca A. Gladdy, M. Wartenberg, A. Fedenko, Giovanni Grignani, Thomas Brodowicz, Michael Montemurro, Albiruni Ryan Abdul Razak, Dario Callegaro, Claudia Sangalli, Ioannis Boukovinas, Patrick Schöffski, M. Deoras-Sutliff, Chandrajit P. Raut, Jyoti Bajpai, C. Jungels, Andrea C. Ferrari, A. Tweddle, Hans Gelderblom, Brian P. Rubin, Nadia Zaffaroni, Paolo G. Casali, Carlo Morosi, M. A. J. van de Sande, P. Merriam, O. Merimsky, Cristina R. Antonescu, G. Sapisochin, Olivier Mir, Sebastian Bauer, Marta Sbaraglia, Bernd Kasper, Stacchiotti S., Miah A.B., Frezza A.M., Messiou C., Morosi C., Caraceni A., Antonescu C.R., Bajpai J., Baldini E., Bauer S., Biagini R., Bielack S., Blay J.Y., Bonvalot S., Boukovinas I., Bovee J.V.M.G., Boye K., Brodowicz T., Callegaro D., De Alava E., Deoras-Sutliff M., Dufresne A., Eriksson M., Errani C., Fedenko A., Ferraresi V., Ferrari A., Fletcher C.D.M., Garcia del Muro X., Gelderblom H., Gladdy R.A., Gouin F., Grignani G., Gutkovich J., Haas R., Hindi N., Hohenberger P., Huang P., Joensuu H., Jones R.L., Jungels C., Kasper B., Kawai A., Le Cesne A., Le Grange F., Leithner A., Leonard H., Lopez Pousa A., Martin Broto J., Merimsky O., Merriam P., Miceli R., Mir O., Molinari M., Montemurro M., Oldani G., Palmerini E., Pantaleo M.A., Patel S., Piperno-Neumann S., Raut C.P., Ravi V., Razak A.R.A., Reichardt P., Rubin B.P., Rutkowski P., Safwat A.A., Sangalli C., Sapisochin G., Sbaraglia M., Scheipl S., Schoffski P., Strauss D., Strauss S.J., Sundby Hall K., Tap W.D., Trama A., Tweddle A., van der Graaf W.T.A., Van De Sande M.A.J., Van Houdt W., van Oortmerssen G., Wagner A.J., Wartenberg M., Wood J., Zaffaroni N., Zimmermann C., Casali P.G., Dei Tos A.P., Gronchi A., University of Helsinki, Department of Oncology, Heikki Joensuu / Principal Investigator, and HUS Comprehensive Cancer Center

Subjects
Cancer Research, sarcoma, diagnosis, Medizin, Disease, HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA, Review, Medical Oncology, Patient advocacy, RISK STRATIFICATION, 0302 clinical medicine, PROPOSAL, CLINICAL CHARACTERISTICS, Medicine, guidelines, Child, 0303 health sciences, ddc:617, treatment, VASCULAR TUMORS, LIVER-TRANSPLANTATION, 3. Good health, IMAGING FINDINGS, diagnosi, epithelioid hemangioendothelioma, Oncology, OF-THE-LITERATURE, 030220 oncology & carcinogenesis, Hemangioendothelioma, Epithelioid, Sarcoma, guideline, management, Human, Adult, medicine.medical_specialty, Consensus, 3122 Cancers, Consensu, Patient Advocacy, Malignancy, Hepatic Epithelioid Hemangioendothelioma, 03 medical and health sciences, Humans, Intensive care medicine, Epithelioid hemangioendothelioma, 030304 developmental biology, business.industry, SOFT-TISSUE, medicine.disease, Rare cancer, Vascular Tumors, SARCOMAS, business
Abstract

Epithelioid hemangioendothelioma (EHE) is an ultra-rare, translocated, vascular sarcoma. EHE clinical behavior is variable, ranging from that of a low-grade malignancy to that of a high-grade sarcoma and it is marked by a high propensity for systemic involvement. No active systemic agents are currently approved specifically for EHE, which is typically refractory to the antitumor drugs used in sarcomas. The degree of uncertainty in selecting the most appropriate therapy for EHE patients and the lack of guidelines on the clinical management of the disease make the adoption of new treatments inconsistent across the world, resulting in suboptimal outcomes for many EHE patients. To address the shortcoming, a global consensus meeting was organized in December 2020 under the umbrella of the European Society for Medical Oncology (ESMO) involving >80 experts from several disciplines from Europe, North America and Asia, together with a patient representative from the EHE Group, a global, disease-specific patient advocacy group, and Sarcoma Patient EuroNet (SPAEN). The meeting was aimed at defining, by consensus, evidence-based best practices for the optimal approach to primary and metastatic EHE. The consensus achieved during that meeting is the subject of the present publication., Highlights • This consensus paper provides key recommendations on the management of epithelioid hemangioendothelioma (EHE). • Recommendations followed a consensus meeting between experts and a representative of the EHE advocacy group and SPAEN. • Authorship includes a multidisciplinary group of experts from different institutions from Europe, North America and Asia.

Published
2021
Full Text
View/download PDF

42. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

Laurence Brugières, K. Sundby Hall, Bruce Morland, Ioannis Boukovinas, Rolf D. Issels, Sebastian Bauer, D.A. Krakorova, Angela Buonadonna, E. de Álava, Nathalie Gaspar, P. Picci, Palma Dileo, Hans Gelderblom, Bernadette Brennan, Javier Martin Broto, Maria Abbondanza Pantaleo, Paul C Jutte, Ian Judson, Suzanne E. J. Kaal, B. Hassan, Ruth Ladenstein, Alexander Fedenko, Patrick Schöffski, Jean-Yves Blay, A. Le Cesne, Peter Hohenberger, Virginia Ferraresi, Sandra J. Strauss, Michael Montemurro, Robin L. Jones, Peter Reichardt, Stefan S. Bielack, Mikael Eriksson, Stefan Sleijfer, Akmal Safwat, Heikki Joensuu, Rick L. Haas, Bernd Kasper, Hannu T. Aro, Judith V.M.G. Bovée, Jeremy Whelan, A.M. Frezza, Antonio López Pousa, Stefanie Hecker-Nolting, Thomas Brodowicz, R. Biagini, Silvia Stacchiotti, S. Ferrari, Sylvie Bonvalot, S. Piperno-Neumann, Leo Kager, F. van Coevorden, Olga Zaikova, R. Piana, Catharina Dhooge, Piotr Rutkowski, M.H. Robinson, Ofer Merimsky, Katerina Kopeckova, X.G. del Muro, W.T.A. van der Graaf, Paolo G. Casali, N. Abecassis, Eva Wardelmann, Silvia Gasperoni, Giovanni Grignani, A. P. Dei Tos, Andrea Ferrari, Franca Fagioli, Alessandro Gronchi, Thierry Gil, Iwona Lugowska, M. Unk, Man, Biomaterials and Microbes (MBM), Public Health Research (PHR), ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Medical Oncology, Casali, P.G., Bielack, S., Abecassis, N., Aro, H.T., Bauer, S., Biagini, R., Bonvalot, S., Boukovinas, I., Bovee, J.V.M.G., Brennan, B., Brodowicz, T., Broto, J.M., Brugières, L., Buonadonna, A., De Álava, E., Dei Tos, A.P., Del Muro, X.G., Dileo, P., Dhooge, C., Eriksson, M., Fagioli, F., Fedenko, A., Ferraresi, V., Ferrari, A., Ferrari, S., Frezza, A.M., Gaspar, N., Gasperoni, S., Gelderblom, H., Gil, T., Grignani, G., Gronchi, A., Haas, R.L., Hassan, B., Hecker-Nolting, S., Hohenberger, P., Issels, R., Joensuu, H., Jones, R.L., Judson, I., Jutte, P., Kaal, S., Kager, L., Kasper, B., Kopeckova, K., Krákorová, D.A., Ladenstein, R., Le Cesne, A., Lugowska, I., Merimsky, O., Montemurro, M., Morland, B., Pantaleo, M.A., Piana, R., Picci, P., Piperno-Neumann, S., Pousa, A.L., Reichardt, P., Robinson, M.H., Rutkowski, P., Safwat, A.A., Schöffski, P., Sleijfer, S., Stacchiotti, S., Strauss, S.J., Sundby Hall, K., Unk, M., Van Coevorden, F., Van Der Graaf, W.T.A., Whelan, J., Wardelmann, E., Zaikova, O., and Blay, J.Y.

Subjects
0301 basic medicine, Oncology, Biopsy, Medizin, Aftercare, CHILDRENS-ONCOLOGY-GROUP, Survivorship, Medical Oncology, 0302 clinical medicine, HIGH-DOSE CHEMOTHERAPY, Positron Emission Tomography Computed Tomography, Antineoplastic Combined Chemotherapy Protocols, GIANT-CELL TUMOR, Orthopedic Procedures, PRIMITIVE NEUROECTODERMAL TUMOR, Child, Societies, Medical, Osteosarcoma, SOFT-TISSUE TUMORS, Incidence (epidemiology), Incidence, Age Factors, Hematology, RANDOMIZED CONTROLLED-TRIAL, Magnetic Resonance Imaging, Neoadjuvant Therapy, Europe, Self-Help Groups, Treatment Outcome, 030220 oncology & carcinogenesis, Sarcoma, HIGH-GRADE OSTEOSARCOMA, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9], Adult, medicine.medical_specialty, education, Bone Neoplasms, Bone Sarcoma, Bone and Bones, 03 medical and health sciences, POSITRON-EMISSION-TOMOGRAPHY, Internal medicine, medicine, Humans, Radionuclide Imaging, STUDY-GROUP PROTOCOLS, Neoplasm Staging, ta3126, NONMETASTATIC EWINGS-SARCOMA, business.industry, Cancer, medicine.disease, Long-Term Care, Cancer registry, 030104 developmental biology, Primitive neuroectodermal tumor, Radiotherapy, Adjuvant, Chondrosarcoma, Patient Participation, business
Abstract

Primary bone tumours are rare, accounting for < 0.2% of malignant neoplasms registered in the EUROCARE (European Cancer Registry based study on survival and care of cancer patients) database. Different bone tumour subtypes have distinct patterns of incidence, and each has no more than 0.3 incident cases per 100 000 per year. Osteosarcoma (OS) and Ewing sarcoma (ES) have a relatively high incidence in the second decade of life, whereas chondrosarcoma (CS) is more common in older age.

Published
2018
Full Text
View/download PDF

43. Geriatric Assessment of Older Patients Receiving Trabectedin in First-Line Treatment for Advanced Soft Tissue Sarcomas: The E-TRAB Study from The German Interdisciplinary Sarcoma Group (GISG-13).

Author

Kasper B, Pink D, Rothermundt C, Richter S, Augustin M, Kollar A, Kunitz A, Eisterer W, Gaidzik V, Brodowicz T, Egerer G, Reichardt P, Hohenberger P, and Schuler MK

Abstract

E-TRAB was a non-interventional, prospective trial investigating the feasibility and predictive value of geriatric assessments (GA) in older STS patients treated with trabectedin as first-line therapy. Primary endpoints were overall survival (OS), quality of life and individual clinical benefit assessed by the patient-reported outcome measures QLQ-C30 and PRO-CTCAE. Further, several GA tools were applied and correlated with clinical outcomes and treatment-related toxicities. The final analyses included 69 patients from 12 German-speaking sites. The median age of patients was 78 years (range: 55 to 88). Baseline data on PROs and GA identified a diverse population of older patients with respect to their global health status, although a large proportion of them suffered from limitations, required geriatric help and had a high risk of morbidity. The Cancer and Age Research Group (CARG) score classified 38%, 29% and 23% of the patients with low, intermediate and high risks for therapy-related side effects, respectively. Median OS was 11.2 months [95%CI: 5.6; 19.4]. The study confirmed that trabectedin as first-line treatment in older patients with STS has an acceptable and manageable safety profile. Potential prognostic factors for clinical outcome and therapy-related toxicity were identified among the GA tools. Long Timed Up and Go (TUG) showed a significant correlation to OS and early death, whereas a high CARG score (>9) was associated with an increase in unplanned hospitalizations and the incidence of toxicities grade ≥ 3.

Published
2024
Full Text
View/download PDF

44. Chemotherapy With Eribulin Following Potentially Curative Surgery in Patients With Localized Liposarcoma.

Author

Steinbrecher O, Brodowicz T, Popov P, and Lamm W

Subjects
Humans, Retrospective Studies, Lipopolysaccharides, Liposarcoma drug therapy, Liposarcoma surgery, Liposarcoma pathology, Sarcoma drug therapy, Soft Tissue Neoplasms drug therapy
Abstract

Background/aim: Soft tissue sarcomas are rare and heterogenous malignancies with high recurrence rates following resection and a poor prognosis in advanced stages. Eribulin is used in metastatic soft tissue sarcoma patients, who have failed first line chemotherapy and has been approved for patients with pretreated advanced liposarcoma (LPS) in the United States and Europe following the publication of data of a phase III trial. In addition, no data are available for eribulin as postoperative treatment after potentially curative surgery. We, thus, retrospectively evaluated efficacy and tolerability of adjuvant eribulin in patients with LPS not suitable for intensive chemotherapy in the routine clinical setting., Patients and Methods: In this retrospective single center analysis, efficacy and safety of eribulin were retrospectively evaluated in five high risk LPS patients., Results: Eribulin as treatment was administered to five patients with LPS following surgical resection. Median progression-free survival and overall survival were 12.3 months and 44.3 months, respectively. Toxicity was generally manageable, and grade 3+4 events were rare., Conclusion: Postoperative eribulin may be feasible in selected high risk LPS patients, who are not candidates for intensive chemotherapy regimens. Further prospective trials, however, are needed., (Copyright © 2024, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)

Published
2024
Full Text
View/download PDF

45. High fibrinogen levels are associated with poor survival in patients with liposarcoma.

Author

Peschek LS, Hobusch GM, Funovics PT, Willegger M, Schmid MP, Amann G, Lamm W, Brodowicz T, Ay C, Windhager R, and Panotopoulos J

Subjects
Humans, Retrospective Studies, Prognosis, Fibrinogen metabolism, Proportional Hazards Models, Kaplan-Meier Estimate, Liposarcoma, Sarcoma, Hemostatics
Abstract

The aim of this study was to evaluate whether (preoperative) plasma levels of fibrinogen, an essential clotting and acute phase protein, are associated with the prognosis of patients with a liposarcoma, a subtype of sarcoma derived from adipose tissue. We performed a retrospective cohort study of 158 patients with liposarcoma treated at the Department of Orthopaedics of the Medical University of Vienna in Austria from May 1994 to October 2021. Kaplan-Meier curves as well as uni- and multivariable Cox proportional hazard models were performed to evaluate the association between fibrinogen levels and overall survival. Elevated fibrinogen was associated with adverse overall survival in cause specific hazards analysis of mortality (hazard ratio [HR] per 10 mg/dL increase: 1.04; 95% CI 1.02-1.06; p < 0.001). This association prevailed in multivariable analysis after adjustment for AJCC tumor stage (HR 1.03; 95% CI 1.01-1.05; p = 0.013). Increasing levels of fibrinogen, a routinely available and inexpensive parameter, predicts the risk of mortality in patients with liposarcoma., (© 2023. The Author(s).)

Published
2023
Full Text
View/download PDF

46. Overall survival with cetuximab every-2-weeks versus standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumour location.

Author

Kasper S, Foch C, Esser R, Lamy FX, Zhang A, Cheng AL, Rouyer M, Brodowicz T, and Zielinski C

Subjects
Humans, Cetuximab therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Proto-Oncogene Proteins p21(ras), Colorectal Neoplasms drug therapy, Colorectal Neoplasms genetics, Antineoplastic Agents, Immunological therapeutic use, Colonic Neoplasms drug therapy, Rectal Neoplasms drug therapy
Abstract

Competing Interests: Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: S. Kasper discloses honoraria (self) from Merck, Amgen, Roche, Sanofi, Aventis, Servier, BMS, MSD, Pierre Fabre and Lilly; honoraria (institution) from Merck, BMS, Amgen, Roche, and Lilly; advisory/consultancy roles with Merck, Amgen, Roche, Sanofi, Aventis, Servier, BMS, MSD, Novartis, Pierre Fabre and Lilly; research grants/funding (self) from Merck, Roche, BMS and Lilly; research grants/funding (institution) from Merck, Roche, BMS and Lilly; travel/accommodation expenses from Merck, Amgen, Roche, Sanofi, Aventis, Servier, and Lilly. C. Foch is a full-time employee of Merck Healthcare KGaA, Darmstadt, Germany. R. Esser was a full-time employee of Merck Healthcare KGaA, Darmstadt, Germany, during the work that is the subject of this letter and holds shares of Merck KGaA. F-X Lamy was a full-time employee of Merck Healthcare KGaA, Darmstadt, Germany during the work that is the subject of this letter. A. Zhang is a full-time employee of Merck Serono Co., Ltd., Beijing, China, an affiliate of Merck KGaA. T. Brodowicz discloses personal fees from Roche (lecture fee), Amgen (lecture fee, advisory board), Bayer (lecture fee, advisory board), Novartis (lecture fee, advisory board), PharmaMar (lecture fee, advisory board), Eisai (lecture fee, advisory board), and Lilly (lecture fee, advisory board), outside the submitted work. C. Zielinski discloses consultancy with Roche, Novartis, BMS, MSD, Imugene, ARIAD, Pfizer, Merrimack, Merck KGaA, FibroGen, AstraZeneca, Tesaro, Gilead, Servier, Shire, Lilly, and Athenex, and speaker's honoraria from Roche, Novartis, BMS, MSD, Imugene, ARIAD, Pfizer, Merrimack, Merck KGaA, FibroGen, AstraZeneca, Tesaro, Gilead, Servier, Shire, Lilly, and Athenex. All remaining authors have nothing to disclose.

Published
2023
Full Text
View/download PDF

47. Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022.

Author

Rothermundt C, Andreou D, Blay JY, Brodowicz T, Desar IME, Dileo P, Gelderblom H, Haas R, Jakob J, Jones RL, Judson I, Kunz WG, Liegl-Atzwanger B, Lindner LH, Messiou C, Miah AB, Reichardt P, Szkandera J, van der Graaf WTA, van Houdt WJ, Wardelmann E, and Hofer S

Subjects
Humans, Forecasting, Consensus, Surveys and Questionnaires, Sarcoma therapy, Sarcoma drug therapy, Soft Tissue Neoplasms diagnosis, Soft Tissue Neoplasms therapy
Abstract

Background: Owing to the rarity and heterogeneity in biology and presentation, there are multiple areas in the diagnosis, treatment and follow-up of soft tissue sarcoma (STS), with no, low-level or conflicting evidence., Methods: During the first Consensus Conference on the State of Science in Sarcoma (CSSS), we used a modified Delphi process to identify areas of controversy in the field of sarcoma, to name topics with limited evidence-based data in which a scientific and knowledge gap may remain and a consensus statement will help to guide patient management. We determined scientific questions which need to be addressed in the future in order to generate evidence and to inform physicians and caregivers in daily clinical practice in order to improve the outcomes of patients with sarcoma. We conducted a vote on STS key questions and controversies prior to the CSSS meeting, which took place in May 2022., Results: Sixty-two European sarcoma experts participated in the survey. Sixteen strong consensus (≥95%) items were identified by the experts, as well as 30 items with a ≥75% consensus on diagnostic and therapeutic questions. Ultimately, many controversy topics remained without consensus., Conclusions: In this manuscript, we summarise the voting results and the discussion during the CSSS meeting. Future scientific questions, priorities for clinical trials, registries, quality assurance, and action by stakeholders are proposed. Platforms and partnerships can support innovative approaches to improve management and clinical research in STS., Competing Interests: Conflict of interest statement The authors declare following conflicts of interest: CR: Consulting or Advisory Role (Payment to Institution): Bayer (Schweiz) AG, Bristol-Myers Squibb, Ipsen, MSD Oncology, Pfizer; Consulting or Advisory Role (Payment to me): Merck (Schweiz) AG; Travel Expenses (Payment to me): PharmaMar; Research Funding (Payment to Institution): Astellas Pharma AG. DA: has received institutional research support from Implantcast GmbH and invited speaker fees from PharmaMar.WGK: served as advisor to Bristol Myers Squibb, unrelated. JYB: grants or research support from AstraZeneca, Bayer, Bristol Myers Squibb, Deciphera, Glaxo SmithKline, Merck Sharp & Dohme, Novartis, PharmaMar, and Roche; has an advisory or board member role in Innate Pharma; and receives honorarium from Bayer, Deciphera, Novartis, and Roche. ID: no COI. PD: Honoraria for consultancy or advisory role: Ayala Pharmaceuticals, Deciphera. RH: no COI. JJ: has received travel expenses or honoraria for participation in advisory boards or invited speaker fees from PharmaMar, Pfizer and Belpharma. LHL: Honoraria and compensation for advisory boards: Boehringer Ingelheim, Novartis, Lilly, Eisai, EL Medconsult, Roche; Travel and research grants: Dr. Sennewald Medizintechnik; Travel grants: PharmaMar; Stockownerships: Thermosome (co-founder) CM: no COI. ABM: Trustee Sarcoma UK, no other conflict of interest. TB: reports personal fees from PharmaMar and Deciphera (lecture fee, advisory board) ABM: Trustee Sarcoma UK, no other conflict of interest. RLJ: Receipt of grants/research support: MSD, GSK. Receipt of consultation fees: Adaptimmune, Astex, Athenex, Bayer, Boehringer Ingelheim, Blueprint, Clinigen, Eisai, Epizyme, Daichii, Deciphera, Immunedesign, Immunicum, Karma Oncology, Lilly, Merck, Mundipharma, Pharmamar, Springworks. SynOx, Tracon, Up to Date. IJ: No conflicts of interest. PR: has received honoraria for participation in advisory boards for Bayer, Novartis, Roche, Deciphera, Mundibiopharma, PharmaMar, Blueprint Medicines, GSK, Boehringer Ingelheim and invited speaker fees from Clinigen, Deciphera, PharmaMar, Boehringer Ingelheim. JS: Participation in advisory boards or invited speaker fees: PharmaMar, Bayer, Roche, Lilly, Amgen; Travel expenses: PharmaMar, Roche, Lilly, Amgen, Bristol Myers Squibb; Research funding: PharmaMar, Roche, Eisai. WvdG: research grant funding from Eli Lilly, advisory board participation Springworks, Bayer, PTC Therapeutics – all to the institute. WJvH: received institutional honoraria for participation in advisory board for Belpharma, invited speaker fees from Amgen andreports expert testimony for Sanofi and MSD and personal travel grant from Novartis and institutional research grant from BMS. EW: has received honoraria for participation in advisory boards or invited speaker fees from Bayer, Roche, Deciphera, Boehringer Ingelheim, Bristol Myers Squibb, PharmaMar. SH: no COI., (Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)

Published
2023
Full Text
View/download PDF

48. Eribulin in Patients with Liposarcoma and Leiomyosarcoma: A Retrospective Single-Center Experience.

Author

Steinbrecher O, Brodowicz T, Raderer M, Scharrer A, Fabsits J, and Lamm W

Subjects
Adult, Humans, Retrospective Studies, Lipopolysaccharides therapeutic use, Leiomyosarcoma drug therapy, Leiomyosarcoma pathology, Liposarcoma drug therapy, Liposarcoma pathology
Abstract

Introduction: Soft tissue sarcomas are rare and heterogenous malignancies with a poor prognosis in advanced disease stages. Eribulin is used in metastatic liposarcoma (LPS) patients, who have failed first-line chemotherapy and has been approved for use in patients with LPS in the USA and Europe due to its efficacy in this histological subtype in a phase 3 trial. We have evaluated efficacy and tolerability of eribulin in LPS and leiomyosarcoma (LMS) patients in the routine clinical setting at our department., Methods: In this retrospective single-center analysis, efficacy and safety of eribulin were retrospectively evaluated in advanced LPS and LMS patients at the Division of Oncology, Medical University of Vienna., Results: A total of 32 adult patients treated with eribulin were identified and included in this analysis. Overall response rate was 9.4% for all patients, with one patient with LPS and two patients with LMS showing a partial response. Disease control rate (partial response plus stable disease) for all patients was 50% (LPS: 47.1%; LMS 53.3%). No statistically significant difference in median progression-free survival and overall survival was detected between patients with LPS and LMS (p = 0.807 and p = 0.519, respectively). Patients with LMS (n = 2) had received fewer previous therapy lines than patients with LPS (n = 14) (≤ previous treatment lines, p < 0.001). Toxicity was generally manageable, and grade 3 + 4 events were rare., Conclusion: The activity and tolerability of eribulin in LPS as in well in LMS patients in the routine clinical setting is comparable to outcomes reported in published phase 3 trials., (© 2022 The Author(s). Published by S. Karger AG, Basel.)

Published
2023
Full Text
View/download PDF

49. Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of Votrient ® in Angiosarcoma) Phase II Trial of the German Interdisciplinary Sarcoma Group (GISG-06).

Author

Pink D, Andreou D, Bauer S, Brodowicz T, Kasper B, Reichardt P, Richter S, Lindner LH, Szkandera J, Grünwald V, Kebenko M, Kirchner M, and Hohenberger P

Abstract

We aimed to evaluate the efficacy and toxicity of paclitaxel combined with pazopanib in advanced angiosarcoma (AS). The primary end point was progression-free survival (PFS) rate at six months (PFSR6). Planned accrual was 44 patients in order to detect a PFSR6 of >55%, with an interim futility analysis of the first 14 patients. The study did not meet its predetermined interim target of 6/14 patients progression-free at 6 months. At the time of this finding, 26 patients had been enrolled between July 2014 and April 2016, resulting in an overrunning of 12 patients. After a median follow-up of 9.5 (IQR 7.7-15.4) months, PFSR6 amounted to 46%. Two patients had a complete and seven patients a partial response. Patients with superficial AS had a significantly higher PFSR6 (61% vs. 13%, p = 0.0247) and PFS (11.3 vs. 2.7 months, p < 0.0001) compared to patients with visceral AS. The median overall survival in the entire cohort was 21.6 months. A total of 10 drug-related serious adverse effects were reported in 5 patients, including a fatal hepatic failure. Although our study did not meet its primary endpoint, the median PFS of 11.6 months in patients with superficial AS appears to be promising. Taking recent reports into consideration, future studies should evaluate the safety and efficacy of VEGFR and immune checkpoint inhibitors with or without paclitaxel in a randomized, multiarm setting.

Published
2021
Full Text
View/download PDF

50. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.

Author

Starzer AM, Berghoff AS, Hamacher R, Tomasich E, Feldmann K, Hatziioannou T, Traint S, Lamm W, Noebauer-Huhmann IM, Furtner J, Müllauer L, Amann G, Bauer S, Schildhaus HU, Preusser M, Heller G, and Brodowicz T

Subjects
Adult, Aged, Aged, 80 and over, Austria, Bone Neoplasms genetics, Bone Neoplasms immunology, Bone Neoplasms mortality, CpG Islands, Epigenomics, Female, Germany, Humans, Immune Checkpoint Inhibitors adverse effects, Lymphocytes, Tumor-Infiltrating immunology, Male, Middle Aged, Osteosarcoma genetics, Osteosarcoma immunology, Osteosarcoma mortality, Programmed Cell Death 1 Receptor immunology, Progression-Free Survival, Retrospective Studies, Sarcoma genetics, Sarcoma immunology, Sarcoma mortality, Signal Transduction, Soft Tissue Neoplasms genetics, Soft Tissue Neoplasms immunology, Soft Tissue Neoplasms mortality, Time Factors, Tumor Microenvironment, Young Adult, Bone Neoplasms drug therapy, DNA Methylation, Epigenome, Immune Checkpoint Inhibitors therapeutic use, Lymphocytes, Tumor-Infiltrating drug effects, Osteosarcoma drug therapy, Programmed Cell Death 1 Receptor antagonists & inhibitors, Sarcoma drug therapy, Soft Tissue Neoplasms drug therapy
Abstract

Background: Some sarcomas respond to immune checkpoint inhibition, but predictive biomarkers are unknown. We analyzed tumor DNA methylation profiles in relation to immunological parameters and response to anti-programmed cell death 1 (anti-PD-1) immune checkpoint inhibitor (ICI) therapy in patients with sarcoma., Patients and Methods: We retrospectively identified adult patients who had received anti-PD-1 ICI therapy for recurrent sarcoma in two independent centers. We performed (1) blinded radiological response evaluation according to immune response evaluation criteria in solid tumors (iRECIST) ; (2) tumor DNA methylation profiling of >850,000 probes using Infinium MethylationEPIC microarrays; (3) analysis of tumor-infiltrating immune cell subsets (CD3, CD8, CD45RO, FOXP3) and intratumoral expression of immune checkpoint molecules (PD-L1, PD-1, LAG-3) using immunohistochemistry; and (4) evaluation of blood-based systemic inflammation scores (neutrophil-to-lymphocyte ratio, leucocyte-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio). Response to anti-PD-1 ICI therapy was bioinformatically and statistically correlated with DNA methylation profiles and immunological data., Results: 35 patients (median age of 50 (23-81) years; 18 females, 17 males; 27 soft tissue sarcomas; 8 osteosarcomas) were included in this study. The objective response rate to anti-PD-1 ICI therapy was 22.9% with complete responses in 3 out of 35 and partial responses in 5 out of 35 patients. Adjustment of DNA methylation data for tumor-infiltrating immune cells resulted in identification of methylation differences between responders and non-responders to anti-PD-1 ICI. 2453 differentially methylated CpG sites (DMPs; 2043 with decreased and 410 with increased methylation) were identified. Clustering of sarcoma samples based on these DMPs revealed two main clusters: methylation cluster 1 (MC1) consisted of 73% responders and methylation cluster 2 (MC2) contained only non-responders to anti-PD-1 ICI. Median progression-free survival from anti-PD-1 therapy start of MC1 and MC2 patients was 16.5 and 1.9 months, respectively (p=0.001). Median overall survival of these patients was 34.4 and 8.0 months, respectively (p=0.029). The most prominent DNA methylation differences were found in pathways implicated in Rap1 signaling, focal adhesion, adherens junction Phosphoinositide 3-kinase (PI3K)-Akt signaling and extracellular matrix (ECM)-receptor interaction., Conclusions: Our data demonstrate that tumor DNA methylation profiles may serve as a predictive marker for response to anti-PD-1 ICI therapy in sarcoma., Competing Interests: Competing interests: AS has received travel support from PharmaMar. AB has research support from Daiichi Sankyo and Roche; honoraria for lectures, consultation or advisory board participation from Roche Bristol-Meyers Squibb, Merck, Daiichi Sankyo; as well as travel support from Roche, Amgen, Daiichi Sankyo and AbbVie. MP has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen. The following for-profit companies have supported clinical trials and contracted research conducted by MP with payments made to his institution: Böhringer-Ingelheim, Bristol-Myers Squibb, Roche, Daiichi Sankyo, Merck Sharp & Dome, Novocure, GlaxoSmithKline, AbbVie. TB reports personal fees from Roche (lecture fee), personal fees from Amgen (lecture fee, advisory board), personal fees from Bayer (lecture fee, advisory board), personal fees from Novartis (lecture fee, advisory board), personal fees from PharmaMar (lecture fee, advisory board), personal fees from Eisai (lecture fee, advisory board), personal fees from Eli Lilly (lecture fee, advisory board), outside the submitted work. RH is supported by Clinician Scientist Program of the University Medicine Essen Clinician Scientist Academy (UMEA) sponsored by faculty of medicine and Deutsche Forschungsgemeinschaft (DFG). RH has received travel grants from Lilly, Novartis and PharmaMar, as well as fees from Lilly outside of the submitted work. SB reports personal fees from Deciphera, grants from Incyte, grants and personal fees from Blueprint Medicines, personal fees from Lilly, grants and personal fees from Novartis, personal fees from Daichii-Sankyo, personal fees from Plexxikon, personal fees from Exelixis, personal fees from Bayer, other from Pfizer, during the conduct of the study; personal fees from Pharmamar, personal fees from Lilly, personal fees from Roche, personal fees from GSK, outside the submitted work. All other authors report no conflicts of interest concerning this specific publication., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results